Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13953042 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2F2RL1ALOX5POLBCALM1 | |
| SCHEMBL14499239 | 0.72 | KMT2A (0.45) | SMN1; SMN2KMT2AF2RL1ALOX5 | |
| SCHEMBL13953254 | 0.67 | SMN1; SMN2 (0.43) | SMN1; SMN2KMT2AF2RL1ALOX5POLB | |
| SCHEMBL13953253 | 0.66 | ALOX5 (0.45) | SMN1; SMN2KMT2AF2RL1ALOX5 | |
| SCHEMBL7220797 | 0.65 | ACACB (0.46) | SMN1; SMN2KMT2AF2RL1POLB | |
| SCHEMBL7425458 | 0.64 | SMN1; SMN2 (0.54) | SMN1; SMN2KMT2AF2RL1MEN1POLB | |
| SCHEMBL7216025 | 0.64 | ALDH1A1 (0.42) | SMN1; SMN2KMT2ARAB9AMEN1NPC1 | |
| SCHEMBL13675862 | 0.64 | CALM1 (0.50) | KMT2AKDM4EALOX5POLBCALM1 | |
| SCHEMBL27446239 | 0.64 | SMN1; SMN2 (0.81) | SMN1; SMN2POLB | |
| SCHEMBL8495718 | 0.64 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2AF2RL1ALOX5POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042772-A1 | COMPOUNDS AND METHODS OF TREATING INSULIN RESISTANCE AND CARDIOMYOPATHY | TRANSITION THERAPEUTICS INC. (CA) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042772-A1 | COMPOUNDS AND METHODS OF TREATING INSULIN RESISTANCE AND CARDIOMYOPATHY | CPT1A, CPT1B, PNLIP | SMN1; SMN2 689/4885KMT2A 4086/4885F2RL1 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.